www.ejcancer.com

• charset: UTF-8
• name: name content: Home Page: European Journal of Cancer
• name: robots content: noarchive
• name: event_group_key content: 3514ae38-65e5-4d59-8d30-56c67c6aa770
• name: viewport content: width=device-width,initial-scale=1,maximum-scale=1, user-scalable=1
• name: twitter:card content: summary_large_image
• name: apple-itunes-app content: app-id=461022524
• name: google-play-app content: app-id=com.elsevier.gmr.ejc
• name: tdm-reservation content: 1
• name: tdm-policy content: https://www.elsevier.com/tdm/tdmrep-policy.json
• equiv: X-UA-Compatible content: IE=edge
• name: pbContext content: ;requestedJournal:journal:ejc;page:string:Home Page;ctype:string:Journal Content;pageGroup:string:Publication Page;wgroup:string:Migrated Websites;journal:journal:ejcold;website:website:ejc-site;product:product:elsevier\:product\:ha
• equiv: origin-trial content: AlK2UR5SkAlj8jjdEc9p3F3xuFYlF6LYjAML3EOqw1g26eCwWPjdmecULvBH5MVPoqKYrOfPhYVL71xAXI1IBQoAAAB8eyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3NTgwNjcxOTksImlzU3ViZG9tYWluIjp0cnVlfQ==
• equiv: origin-trial content: Amm8/NmvvQfhwCib6I7ZsmUxiSCfOxWxHayJwyU1r3gRIItzr7bNQid6O8ZYaE1GSQTa69WwhPC9flq/oYkRBwsAAACCeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiV2ViVmlld1hSZXF1ZXN0ZWRXaXRoRGVwcmVjYXRpb24iLCJleHBpcnkiOjE3NTgwNjcxOTksImlzU3ViZG9tYWluIjp0cnVlfQ==
• equiv: origin-trial content: A9nrunKdU5m96PSN1XsSGr3qOP0lvPFUB2AiAylCDlN5DTl17uDFkpQuHj1AFtgWLxpLaiBZuhrtb2WOu7ofHwEAAACKeyJvcmlnaW4iOiJodHRwczovL2RvdWJsZWNsaWNrLm5ldDo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9
• equiv: origin-trial content: A93bovR+QVXNx2/38qDbmeYYf1wdte9EO37K9eMq3r+541qo0byhYU899BhPB7Cv9QqD7wIbR1B6OAc9kEfYCA4AAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXN5bmRpY2F0aW9uLmNvbTo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9
• equiv: origin-trial content: A1S5fojrAunSDrFbD8OfGmFHdRFZymSM/1ss3G+NEttCLfHkXvlcF6LGLH8Mo5PakLO1sCASXU1/gQf6XGuTBgwAAACQeyJvcmlnaW4iOiJodHRwczovL2dvb2dsZXRhZ3NlcnZpY2VzLmNvbTo0NDMiLCJmZWF0dXJlIjoiQUlQcm9tcHRBUElNdWx0aW1vZGFsSW5wdXQiLCJleHBpcnkiOjE3NzQzMTA0MDAsImlzU3ViZG9tYWluIjp0cnVlLCJpc1RoaXJkUGFydHkiOnRydWV9

• Skip to Main Content
• Skip to Main Menu
• Ok
• Forgot password?
• Create a Free Account
• http://www.ejcancer.com/
• Log in
• Get Institutional Access
• Register
• Skip menu
• http://www.ejcancer.com/issue/S0959-8049(25)X0020-4
• Articles in Press
• http://www.ejcancer.com/inprogress
• Current Issue
• Past Issues
• Special Issues
• European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023
• Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines
• EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023
• Potential Induction of Protective Anti-Tumor Immune Response in Cancer Patients by Oncolytic Viruses Containing the
• Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion Solid Tumors in Spain (SPAINTRK)
• Clinico-radiological Outcomes after Discontinuation of Sorafenib in Non-Abdominal Desmoid-type Fibromatosis: Final Results from a Phase-II SORASTOP Study from India
• Author Information
• About the Journal
• About Open Access
• http://www.ejcancer.com/pb/assets/raw/Health%20Advance/journals/ejc/EJC_Author_Form-1391784308107.pdf
• View all European Journal of Cancer Podcasts
• Society Information
• Editorial Board
• Abstracting/Indexing
• Subscribe
• Activate Online Access
• Contact Information
• Sign Up for Alerts
• Advanced search
• http://www.ejcancer.com/javascript:void(0)
• View Aims & Scope
• View Guide for Authors
• View Editorial Board
• Listen Now
• Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
• Listen Now
• Increasing frequency of non-smoking lung cancer: Presentation of patients with early disease to a tertiary institution in the UK
• Listen Now
• Radiotherapy access in Belgium: How far are we from evidence-based utilisation?
• Listen Now
• Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects
• Letter re: Patient-related prognostic factors in older adults with head and neck cancer: The EGeSOR clinical trial"
• The basis for future personalized therapy approaches – Machine learning-generated 1-year survival rate, metastatic status and therapy-dependent survival in pancreatic cancer patients
• Ambient air pollution and survival in SCLC/LCNEC: Analysis of a single centre retrospective cohort
• Braf-mutant metastatic non–small-cell lung cancer: Real world data from the Italian biomarker atlas database
• EORTC Society News 2025
• Long-term outcomes among patients who respond within the first year to nivolumab plus ipilimumab or nivolumab monotherapy: A pooled analysis in 935 patients
• The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients
• Classic Hodgkin Lymphoma: The LYSA pragmatic guidelines
• Home
• Access for Developing Countries
• EJC Supplements
• EJC Author Form
• Subscribe
• Sign up for e-Alerts
• RSS Feed

• Submit
• Supports
• https://www.editorialmanager.com/ejc/default2.aspx
• https://researcheracademy.elsevier.com/
• EORTC
• EUSOMA
• PracticeUpdate
• Info for Advertisers
• Go to Product Catalog
• Twitter
• https://www.editorialmanager.com/ejc
• Researcher Academy
• Submit Manuscript
• Privacy Policy
• Terms and Conditions
• Accessibility
• Help & Contact
• https://www.relx.com

            Domain Name: EJCANCER.COM
Registrar: SafeNames Ltd.
Domain Status: client delete prohibited
Domain Status: client transfer prohibited
Domain Status: client update prohibited
Creation Date: 2002-04-08T09:40:04Z
Registry Expiry Date: 2027-04-08T09:40:04Z
Updated Date: 2026-04-08T23:51:57Z
Name Server: NS1.REEDELSEVIER.COM
Name Server: NS2.REEDELSEVIER.COM
Name Server: NS3.REEDELSEVIER.COM
REGISTRAR Contact: SafeNames Ltd.
>>> Last update of RDAP database: 2026-06-08T01:24:12Z         

			Sitemap: https://www.ejcancer.com/sitemap-index-1.txt
Sitemap: https://www.ejcancer.com/custom_pages.gz

User-agent: *
Disallow: /action
Disallow: /help
Disallow: /search
Disallow: /feedback
Disallow: /rss
Disallow: /action/clickThrough
Disallow: /action/showLogin
Disallow: /page/account-confirmation-thanks
Disallow: /media
Disallow: /medical-research
Disallow: /servlet/linkout
Disallow: /na101/
Disallow: /na101v1/
Disallow: /na102/
Disallow: /doi/mlt/
Disallow: /cms/attachment/92c526c4-ef1f-4065-b12b-ca4ae0f3e84f/gr1*
Disallow: /personalize/addFavoritePublication
Disallow: /pb/widgets/*
Allow: /action/showJournal
Allow: /action/showXml
Allow: /series
Allow: /isbn
Allow: /doi/book
Allow: /.well-known/*

User-agent: Twitterbot
Allow: /

User-agent: LinkedInBot
Allow: /

User-agent: GPTBot
Disallow: /

User-agent: ChatGPT-User
Disallow: /

User-agent: CCBot
Disallow: /

User-agent: Google-Extended
Disallow: /

User-agent: PerplexityBot
Disallow: /

User-agent: AI2Bot
Disallow: /

User-agent: Amazonbot
Disallow: /

User-agent: anthropic-ai
Disallow: /

User-agent: ClaudeBot
Disallow: /

User-agent: Bytespider
Disallow: /

User-agent: cohere-training-data-crawler
Disallow: /

User-agent: cohere-ai
Disallow: /

User-agent: Diffbot
Disallow: /

User-agent: iAskBot/1.0
Disallow: /

User-agent: meta-externalagent
Disallow: /

User-agent: MistralAI-User
Disallow: /

User-agent: omgili
Disallow: /

User-agent: TimpiBot
Disallow: /

User-agent: YouBot
Disallow: /

Crawl-delay: 1
        

テクニカルSEO

オンページSEO

コンテンツとUX